Just in: $ARTL surges to $6.78, up 39.75%.
1. Catalyst driven by an accelerated FDA approval timeline for its novel therapy platform.
2. Strategic pivot aligns with rising demand for targeted biotech treatments, fueling significant momentum.
3.

26